PCSK9 and metabolic syndrome: Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved by the U.S. Federal Drug Administration (FDA) for treating dyslipidemias.29 We believe that repurposing of a PCSK9 inhibitor may attenuate vascular senescence while also verifying the contribution of PCSK9 to vascular aging.